Adverse effects of bisphosphonates: Implications for osteoporosis management

Mayo Clinic Proceedings

Volumn 84, Issue 7, 2009, Pages 632-638

  Kennel, Kurt A ^a   Drake, Matthew T ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; HYDROXYAPATITE; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ABDOMINAL PAIN; ACUTE PHASE RESPONSE; ALGORITHM; ARTHRALGIA; BONE DENSITY; BONE MASS; BONE METASTASIS; BONE TURNOVER; CALCIUM INTAKE; CANCER RISK; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BINDING; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG INHIBITION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ESOPHAGUS CANCER; EYE INFLAMMATION; EYE PAIN; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE; FRACTURE NONUNION; FRAGILITY FRACTURE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; LONG TERM CARE; MOUTH HYGIENE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; OPTIMAL DRUG DOSE; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PHOTOPHOBIA; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; RECOMMENDED DRUG DOSE; REFLUX ESOPHAGITIS; REVIEW; RISK ASSESSMENT; SECONDARY HYPERPARATHYROIDISM; SENILE OSTEOPOROSIS; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; WORLD HEALTH ORGANIZATION; AGED; DRUG ADMINISTRATION; FEMALE; MALE; MIDDLE AGED;

AGED; ALGORITHMS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; RISK ASSESSMENT;

EID: 67650767002     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.7.632     Document Type: Review

References (33)

1. WHO Fracture Risk Assessment Tool. http://www.shef.ac.uk/FRAX. Accessed June 2, 2009.
2. Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet. 2005;44(6):551-570.
3. Rizzoli R, Greenspan SL, Bone G III, et al; Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res. 2002;17(11):1988-1996.
4. Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab. 2009;94(2):538-544. Epub 2008 Dec 2.
5. Khan SA, Kanis JA, Vasikaran S, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res. 1997;12(10):1700-1707.
6. Greenspan S, Field-Munves E, Tonino R, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2002;77(10):1044-1052.
7. Harris ST, Watts NB, Genant HK, et al; Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282(14):1344-1352.
8. Chesnut CH III, Skag A, Christiansen C, et al; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241-1249. Epub 2004 Mar 29.
9. Black DM, Delmas PD, Eastell R, et al; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.
10. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006;54(6):1838-1846.
11. US Food and Drug Administration. Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa). http://www.fda.gov/medwatch/safety/2008/safety08.htm#Bisphosphonates. Accessed May 29, 2009.
12. Dicuonzo G, Vincenzi B, Santini D, et al. Fever after zoledronic acid administration is due to increase in TNF-α and IL-6. J Interferon Cytokine Res. 2003;23(11):649-654.
13. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use [letter]. N Engl J Med. 2009;360(1):89-90.
14. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research [editorial]. J Bone Miner Res. 2007;22(10):1479-1491.
15. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws [published correction appears in Ann Intern Med. 2006;145(3):235]. Ann Intern Med. 2006;144(10):753-761.
16. Montefusco V, Gay F, Spina F, et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma. 2008;49(11):2156-2162.
17. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65(12):2397-2410.
18. Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res. 2009;24(4):561-574.
19. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation [letter]. N Engl J Med. 2007;356(18):1895-1896.
20. Sørensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008;336(7648):813-816. Epub 2008 Mar 11.
21. Karam R, Camm J, McClung M. Yearly zoledronic acid in postmenopausal osteoporosis [letter]. N Engl J Med. 2007;357(7):712-713.
22. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294-1301. Epub 2004 Dec 14.
23. Bone HG, Hosking D, Devogelaer JP, et al; Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189- 1199.
24. Black DM, Schwartz AV, Ensrud KE, et al; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927-2938.
25. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate [letter]. N Engl J Med. 2008;358(12):1304-1306.
26. Kwek EB, Koh JS, Howe TS. More on atypical fractures of the femoral diaphysis [letter]. N Engl J Med. 2008;359(3):316-317.
27. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009;24(6):1095-1102.
28. Whyte MP. Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. J Bone Miner Res. 2009;24(6):1132-1134.
29. Snijder MB, van Schoor NM, Pluijm SM, van Dam RM, Visser M, Lips P. Vitamin D status in relation to one-year risk of recurrent falling in older men and women. J Clin Endocrinol Metab. 2006;91(8):2980-2985. Epub 2006 May 9.
30. Adami S, Giannini S, Bianchi G, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int. 2009;20(2):239-244. Epub 2008 Jun 13.
31. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281.
32. National Osteoporosis Foundation's updated recommendations for calcium and vitamin D intake. National Osteoporosis Foundation Web site. http://www.nof.org/prevention/calcium-and-VitaminD.htm. Accessed May 29, 2009.
33. Bolland MJ, Grey AB, Horne AM, et al. Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. J Bone Miner Res. 2008;23(8):1304-1308.